Toleranzia
0,365
SEK
+1,96 %
Mindre end 1K følgere
TOL
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Finansielt overblik og estimater
Ownership
+1,96%
-42,61%
-38,55%
-36,19%
-28,43%
-2,41%
-66,2%
-78,46%
-94,46%
Toleranzia is a research company focused on the development of drug candidates for the treatment of autoimmune diseases. The company has developed a platform technology focused on the muscular disease myasthenia gravis. In addition, the technology has been used in other areas such as diabetes and multiple sclerosis. Research collaboration is done together with external partners within the field. The head office is based in Gothenburg.
Læs mereMarkedsværdi
98,9 mio. SEK
Aktieomsætning
9,55 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Finanskalender
6.5
2025
Delårsrapport Q1'25
5.6
2025
Generalforsamling '25
20.8
2025
Delårsrapport Q2'25
ViserAlle indholdstyper
Toleranzia AB: Year-End Report 2024
Toleranzia’s clinical trial application (CTA) for TOL2 approved in Germany while declined in Denmark
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools